const NeuralNetworksCancerRemediation = () => (
  <article>
    <p>
      During my senior year at Central Connecticut State University, I wrote and published a
      thesis exploring a question that sits at the intersection of AI, robotics, and medicine:
      could neural network-guided bio-nanorobots be used to detect and treat cancer at the
      cellular level? This post walks through the core architecture, the neural network models
      involved, and the real-world constraints that make this a hard problem.
    </p>

    <h2>The Problem with Current Cancer Treatment</h2>
    <p>
      Conventional cancer treatments — chemotherapy, radiation — are powerful but imprecise.
      They operate on bulk tissue rather than individual cells, which means healthy cells
      inevitably suffer collateral damage. The appeal of nanorobotics is specificity: agents
      small enough to navigate the human body, locate malignant cells, and deliver a targeted
      response without disturbing surrounding healthy tissue.
    </p>
    <p>
      The question my thesis addressed wasn't whether this is physically possible (nanorobotics
      is an active hardware research area), but whether a viable computational framework could
      be designed — one that uses modern neural network architectures to handle the core tasks
      of navigation, detection, and treatment.
    </p>

    <h2>Architecture Overview</h2>
    <p>
      The proposed system has three functional layers, each driven by a different class of
      neural network:
    </p>
    <ol>
      <li><strong>Body traversal</strong> — RSHNs guided by Graph Neural Networks (GNNs)</li>
      <li><strong>Cancer cell detection</strong> — Convolutional Neural Networks (CNNs)</li>
      <li><strong>Targeted treatment</strong> — Pharmacyte drug delivery upon confirmed detection</li>
    </ol>

    <h2>Layer 1 — Navigation: RSHNs and Graph Neural Networks</h2>
    <p>
      The nanorobots in this framework are modeled as <strong>Reconfigurable Swarm Hybrid
      Nanorobots (RSHNs)</strong> — small, configurable agents that operate collectively rather
      than individually. No single nanorobot is capable of complex reasoning; the swarm is.
    </p>
    <p>
      Navigation through the body's vascular and lymphatic systems is modeled as a graph
      traversal problem. Body cavities, vessels, and tissue boundaries are nodes and edges in
      a biological graph. A <strong>Graph Neural Network (GNN)</strong> learns the structural
      properties of this graph — which paths are viable, where congestion occurs, and how to
      route swarms toward target tissue regions. This avoids the need for hardcoded anatomical
      maps by letting the model generalize from the graph's topology at inference time.
    </p>

    <h2>Layer 2 — Detection: Convolutional Neural Networks</h2>
    <p>
      Once RSHNs reach target tissue, the detection problem becomes one of image classification.
      Nanorobots equipped with biosensors capture structural and chemical data at the cellular
      level. A <strong>Convolutional Neural Network (CNN)</strong> processes this data to
      distinguish malignant cells from healthy ones based on surface protein markers,
      morphological features, and the local cellular environment.
    </p>
    <p>
      CNNs are well-suited here because cancer cell identification is fundamentally a pattern
      recognition task — the same spatial feature extraction that makes CNNs effective for
      image classification translates to identifying the structural signatures of malignancy.
      The model must be lightweight enough to run on or near the nanorobot swarm, which is one
      of the more demanding engineering constraints in the whole system.
    </p>

    <h2>Layer 3 — Treatment: Pharmacytes</h2>
    <p>
      Upon confirmed detection, the relevant RSHNs act as <strong>pharmacytes</strong> —
      drug-carrying nanorobots that release a targeted therapeutic payload directly at the
      malignant cell. Because treatment is triggered only after CNN-confirmed identification,
      healthy tissue is not exposed to the therapeutic agent. This is the specificity that
      conventional treatments can't achieve.
    </p>
    <p>
      The pharmacyte model also allows for adaptive dosing: swarm size, payload concentration,
      and release timing can be tuned dynamically based on the density of detected cancer cells,
      rather than applying a fixed systemic dose.
    </p>

    <h2>Legal and Ethical Considerations</h2>
    <p>
      Any system operating autonomously inside a patient's body carries serious legal and
      ethical weight, and the thesis addresses these directly.
    </p>
    <ul>
      <li>
        <strong>HIPAA compliance</strong> — The biosensor data collected by RSHNs is protected
        medical information. Any real implementation must enforce strict data governance: what
        is transmitted, to whom, and how it is stored.
      </li>
      <li>
        <strong>ACM ethics guidelines</strong> — Autonomous medical AI systems must be
        explainable and contestable. A patient or physician should be able to understand why the
        system identified a particular cell as malignant and challenge that determination before
        treatment is administered.
      </li>
      <li>
        <strong>Informed consent</strong> — Deploying nanorobots inside a patient requires
        explicit, informed consent that covers the scope of autonomous decision-making the
        system performs. Patients should know when and how the AI acts without direct physician
        input.
      </li>
    </ul>

    <h2>Where This Stands</h2>
    <p>
      This is a conceptual and computational framework — not a clinical implementation. The
      hardware side (actually manufacturing and deploying bio-nanorobots at therapeutic scale)
      remains a major open problem in materials science and bioengineering. But the value of
      this kind of systems-level thinking is that it surfaces the hard constraints early:
      model size, latency, explainability, and consent aren't afterthoughts you can bolt on
      later — they have to be designed in from the start.
    </p>
    <p>
      The intersection of AI and nano-scale medicine is one of the areas I find most
      compelling, precisely because the stakes are real and the engineering challenges are
      genuinely hard. If you want to read the full thesis, it's published in the CCSU
      library catalog:
    </p>
    <p>
      <a
        href="https://cscu-ccsu.primo.exlibrisgroup.com/discovery/delivery/01CSCU_CCSU:CCSU_V1/12119319420003453"
        target="_blank"
        rel="noopener noreferrer"
      >
        Neural Network-Guided Nanobots for Cancer Remediation — CCSU Library
      </a>
    </p>
  </article>
);

export default NeuralNetworksCancerRemediation;
